Informa Pharma Intelligence Congratulates Scrip Lifetime Achievement Award Winner on his Nobel Prize
Informa celebrates Sir Greg Winter and his 2018 Nobel Prize for Chemistry
London – October 5th, 2018 – Today, Informa Pharma Intelligence congratulates Sir Greg Winter, the scientist behind one of the pharma and biotech industry’s most notable therapeutic breakthroughs, on his 2018 Nobel Prize award for Chemistry.
Recipient of Informa Pharma Intelligence’s 2015 Scrip Lifetime Achievement Award for his pioneering research into humanizing antibodies, his findings led to the development of the first human antibody, Humira (adalimumab), the world's top-selling drug.
“The team at Informa Pharma Intelligence is proud to see one of our former Lifetime Achievement award winners further recognized for his incredible work by the Nobel Committee. Sir Greg’s pioneering research has had a tremendous impact on the pharma and biotech industry, moving the needle forward on everything from producing antibodies for neutralizing toxins to counteracting autoimmune diseases to curing metastatic cancer. He couldn’t be more deserving of such a prestigious award,” said Phil Jarvis, Head of Insight at Informa Pharma Intelligence.
The first pharmaceutical based on Sir Greg’s method, AbbVie Inc.’s TNF inhibitor Humira (adalimumab), was approved in 2002 and is now used to treat a range of diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. In 2017, Informa Pharma Intelligence listed global Humira sales at $18.4bn and they are expected to approach $21bn in 2020.
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 50alysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
Diffusion PR for Informa Pharma Intelligence